Literature DB >> 30720171

MiR-127-3p targets KIF3B to inhibit the development of oral squamous cell carcinoma.

L Ji1, Z-N Zhu, C-J He, X Shen.   

Abstract

OBJECTIVE: Recently, increased microRNAs have been shown to play an important role in the pathogenesis and progression of human cancers, including oral squamous cell carcinoma (OSCC). In this study, we focused on the function of microRNA-127-3p (miR-127-3p) associated with OSCC carcinogenesis. PATIENTS AND METHODS: MiR-127-3p and KIF3B expressions were observed via quantitative Real-time polymerase chain reaction (qRT-PCR) or Western blot in OSCC. The functions of mR-127-3p and KIF3B were investigated through MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) and transwell assays. And luciferase reporter assay was performed to confirm the relationship between mR-127-3p and KIF3B.
RESULTS: First, down-regulation of miR-127-3p was identified in OSCC, which was associated with malignant clinicopathological features and poor prognosis in OSCC patients. Functionally, overexpression of miR-127-3p led to inhibition of cell proliferation and metastasis in OSCC. Further, KIF3B was confirmed to be a direct target of miR-127-3p. Moreover, upregulation of KIF3B was also observed in OSCC, which promoted tumorigenesis of OSCC. In particular, the upregulation of KIF3B partially attenuated the inhibitory effect of miR-127-3p on the development of OSCC.
CONCLUSIONS: MiR-127-3p targeted KIF3B to inhibit the development of OSCC through suppressing cell proliferation, migration and invasion.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30720171     DOI: 10.26355/eurrev_201901_16877

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

Review 1.  Research progress on KIF3B and related diseases.

Authors:  Lihui Zhou; Lian Ouyang; Keying Chen; Xucan Wang
Journal:  Ann Transl Med       Date:  2019-09

Review 2.  Research progress and clinical application prospects of miRNAs in oral cancer.

Authors:  Long Xing; Zhenghu Feng; Hongbing Nie; Meitian Liu; Yali Liu; Xiaohua Zhang; Haijing Zhou
Journal:  Mol Biol Rep       Date:  2022-06-20       Impact factor: 2.316

3.  Mesenchymal stem cell-derived exosomes block malignant behaviors of hepatocellular carcinoma stem cells through a lncRNA C5orf66-AS1/microRNA-127-3p/DUSP1/ERK axis.

Authors:  Hao Gu; Chao Yan; Haijun Wan; Lin Wu; Junjie Liu; Zhiqiang Zhu; Dazhi Gao
Journal:  Hum Cell       Date:  2021-08-24       Impact factor: 4.374

4.  LncRNA FOXD3-AS1 promoted chemo-resistance of NSCLC cells via directly acting on miR-127-3p/MDM2 axis.

Authors:  Zhaolong Zeng; Guofang Zhao; Huangkai Zhu; Liangqin Nie; Lifeng He; Jiangtao Liu; Rui Li; Shuai Xiao; Gang Hua
Journal:  Cancer Cell Int       Date:  2020-07-29       Impact factor: 5.722

5.  Hsa_circ_0015326 Promotes the Proliferation, Invasion and Migration of Ovarian Cancer Through miR-127-3p/MYB.

Authors:  Cuiying Zhang; Wei Liu; Fei Li; Yang Feng; Yunyun Li; Jia Wang
Journal:  Cancer Manag Res       Date:  2021-03-10       Impact factor: 3.989

6.  Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis.

Authors:  Junjie Cen; Yanping Liang; Yong Huang; Yihui Pan; Guannan Shu; Zhousan Zheng; Xiaozhong Liao; Mi Zhou; Danlei Chen; Yong Fang; Wei Chen; Junhang Luo; Jiaxing Zhang
Journal:  Mol Cancer       Date:  2021-01-20       Impact factor: 27.401

7.  MiR-127-3p targeting CISD1 regulates autophagy in hypoxic-ischemic cortex.

Authors:  Zi-Bin Zhang; Liu-Lin Xiong; Lu-Lu Xue; Yan-Ping Deng; Ruo-Lan Du; Qiao Hu; Yang Xu; Si-Jin Yang; Ting-Hua Wang
Journal:  Cell Death Dis       Date:  2021-03-15       Impact factor: 8.469

8.  Altered Expressions of NF1 and NF1-Related microRNAs as Biomarkers in the Diagnosis of Undifferentiated Pleomorphic Sarcoma.

Authors:  Peng Zhang; Lingling Huang; Pengwei Ma; Xiaoying Niu
Journal:  Front Genet       Date:  2022-04-26       Impact factor: 4.772

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.